Cencora, Inc. (COR) is listed on NYSE and operates in the Medical - Distribution industry (Healthcare sector).
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service,...
| Rating | Analysts |
|---|---|
| Strong Buy | 0 |
| Buy | 33 |
| Hold | 12 |
| Sell | 1 |
| Strong Sell | 0 |
Cencora, Inc., formerly known as AmerisourceBergen Corporation, is a healthcare company specializing in the distribution of pharmaceutical products both in the United States and internationally. Its U.S. Healthcare Solutions segment provides a wide range of services and products, including generic and injectable pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies. The company serves various clients such as hospitals, retail and mail-order pharmacies, medical clinics, and long-term care facilities. Additionally, Cencora offers pharmacy management, consulting services, supply management software, packaging solutions, and clinical trial support. It also provides data analytics and outcomes research for biotechnology and pharmaceutical manufacturers. In the animal health sector, the company distributes pharmaceuticals and other products to the companion and production animal markets. The International Healthcare Solutions segment focuses on pharmaceutical wholesale, global commercialization services, and specialty transportation and logistics for the biopharmaceutical industry. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Over the past three fiscal years, the company has demonstrated a consistent increase in revenue, achieving a compound annual growth rate (CAGR) of 10.7%, with revenue rising from $262.2 billion in 2023 to $321.3 billion in 2025. This growth was accompanied by an improvement in gross and operating margins, which increased by 0.2 percentage points each, reaching 3.2% and 1.1% respectively by 2025. However, net margins experienced a slight decline of 0.18 percentage points, ending at 0.48%. Despite the revenue growth, earnings per share (EPS) showed inconsistency, decreasing from $8.53 in 2023 to $7.96 in 2025, reflecting a CAGR of -3.4%. Cash flow from operations (OCF) and free cash flow (FCF) were inconsistent, with FCF decreasing from $3.45 billion to $3.21 billion, leading to a decline in FCF margin from 1.3% to 1.0%. The company’s net debt increased significantly, from $4.13 billion to $6.35 billion, indicating a rise in leverage. Despite these challenges, the cash conversion ratio improved to 2.47, suggesting that earnings are increasingly backed by actual cash. Additionally, the company reduced its share count by 4.6%, enhancing per-share value creation. However, liquidity remains a concern, with a current ratio below 1, indicating potential challenges in meeting short-term obligations.
Recent developments for Cencora, Inc. (NYSE: COR) highlight significant strategic and financial activities. On March 23, Cencora announced its acquisition of EyeSouth Partners' retina business for $1.1 billion, a move aimed at expanding its Retina Consultants of America division. This acquisition underscores Cencora's strategic initiative to strengthen its position in the healthcare sector. In terms of financial activities, Massachusetts Financial Services Co. MA and Allspring Global Investments Holdings LLC have reduced their holdings in Cencora, selling 89,591 and 40,638 shares, respectively, as of the end of the most recent quarter. Meanwhile, the California Public Employees Retirement System maintains a substantial holding of $184.01 million in Cencora, and Chilton Investment Co. Inc. has acquired new holdings. These transactions reflect varied institutional investor sentiment towards Cencora. Additionally, Cencora is set to release its second-quarter fiscal 2026 earnings, with the announcement scheduled for April 1. This upcoming earnings release will be closely watched by investors for insights into the company's financial health and future guidance. Overall, Cencora's recent activities indicate a focus on strategic growth through acquisitions, while institutional trading shows a mixed outlook among investors.